# Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

> **NCT06392841** · PHASE2 · WITHDRAWN · sponsor: **Qian Qin**

## Conditions studied

- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Deleterious HRR Gene Mutation
- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
- BRIP1 Gene Mutation
- CHEK2 Gene Mutation
- FANCA Gene Mutation
- PALB2 Gene Mutation
- RAD51B Gene Mutation
- RAD54L Gene Mutation

## Interventions

- **DRUG:** Androgen Deprivation Therapy (ADT)
- **DRUG:** Niraparib/Abiraterone Acetate DAT
- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT06392841
- **Lead sponsor:** Qian Qin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-10
- **Primary completion:** 2028-01-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funder withdrew funding.
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06392841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06392841, "Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06392841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*